Moxifloxacin ( DrugBank: Moxifloxacin )

---

9 diseases

ID	Disease name (Link within this page)	Number of trials
2	Amyotrophic lateral sclerosis	1
6	Parkinson disease	4
46	Malignant rheumatoid arthritis	2
49	Systemic lupus erythematosus	1
85	Idiopathic interstitial pneumonia	1
86	Pulmonary arterial hypertension	1
113	Muscular dystrophy	1
240	Phenylketonuria	1
299	Cystic fibrosis	1

2. Amyotrophic lateral sclerosis

---

Clinical trials : 645 /  Drugs : 589 - (DrugBank : 163) / Drug target genes : 150 - Drug target pathways : 225

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01511029 (ClinicalTrials.gov)	January 2012	9/1/2012	Study to Evaluate the QTC Interval in Healthy Volunteers Dosed With Dexpramipexole (QTC = Electrocardiogram (ECG) Interval Measured From the Onset of the QRS Complex to the End of the T Wave Corrected for Heart Rate)	A Single-Center, Randomized, Blinded, Placebo- and Active-Controlled Crossover Study to Evaluate the Effect of Dexpramipexole (BIIB050) on the QTc Interval in Healthy Volunteers	Amyotrophic Lateral Sclerosis	Drug: Dexpramipexole;Drug: Dexpramipexole Placebo;Drug: Moxifloxacin	Knopp Biosciences	NULL	Completed	18 Years	60 Years	Both	68	Phase 1	United States

6. Parkinson disease

---

Clinical trials : 2,307 /  Drugs : 2,007 - (DrugBank : 349) / Drug target genes : 188 - Drug target pathways : 199

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04342273 (ClinicalTrials.gov)	March 31, 2020	8/4/2020	A Through QT/QTc Study of KW-6356	A Through QT/QTc Study of KW-6356 in Japanese Healthy Adults	Parkinson's Disease	Drug: KW-6356;Drug: Placebo;Drug: Moxifloxacin	Kyowa Kirin Co., Ltd.	NULL	Completed	20 Years	54 Years	All	128	Phase 1	Japan
2	NCT03187301 (ClinicalTrials.gov)	August 3, 2017	7/6/2017	A Cardiac Safety Study of an Investigational Drug to See How if Affects the Heart in People With Parkinson's Disease Complicated by Motor Fluctuations OFF Episodes	A Phase 2, Randomized, Double-Blind, Placebo Controlled, 3-Period Crossover, Positive Control, QT-Evaluation Study of APL-130277 in Subjects With Parkinson's Disease Complicated by Motor Fluctuations (OFF Episodes)	Parkinson's Disease;Off Episodes of Parkinson Disease	Drug: APL-130277;Drug: Placebo;Drug: Moxifloxacin	Sunovion	NULL	Completed	18 Years	N/A	All	48	Phase 2	United States;Italy
3	NCT01532115 (ClinicalTrials.gov)	May 2010	23/1/2012	Effect of BIA 9-1067 on Cardiac Repolarization in Healthy Adult Men and Women	A Randomized, Double-blind, Placebo-controlled and Open-label Active-controlled, 4-period Crossover Trial to Evaluate the Effect of BIA 9-1067 on Cardiac Repolarization in Healthy Adult Men and Women	Parkinson Disease	Drug: BIA 9-1067;Drug: Placebo;Drug: moxifloxacin	Bial - Portela C S.A.	NULL	Completed	18 Years	55 Years	Both	64	Phase 1	France
4	NCT00292227 (ClinicalTrials.gov)	January 2006	14/2/2006	Cardiac Effects of Rotigotine Transdermal System in Subjects With Advanced-stage Idiopathic Parkinson's Disease	Double-blind, Randomized, Placebo- and Positive-controlled, Parallel-group Trial to Assess the Potential Electrocardiographic Effects of Rotigotine Transdermal System up to 120 cm2/54.0 mg/Day in Subjects With Advanced-stage Idiopathic Parkinson's Disease: A Thorough QT/QTc Trial.	Parkinson's Disease	Drug: Rotigotine;Other: Placebo;Drug: Moxifloxacin infusion;Other: Placebo infusion	UCB Pharma	NULL	Completed	18 Years	N/A	All	130	Phase 1	South Africa

46. Malignant rheumatoid arthritis

---

Clinical trials : 4,356 /  Drugs : 2,567 - (DrugBank : 415) / Drug target genes : 192 - Drug target pathways : 228

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2009-011044-20-GB (EUCTR)	08/04/2009	14/04/2009	A Single-Centre, Double-blind, Double-dummy, Randomised, Placebo Controlled, Four Period Crossover Study to Assess the Effect of Single Oral Doses of AZD5672 (600mg and 150mg) on QT/QTc Interval, Compared to Placebo, using Moxifloxacin (Avelox®) as a Positive Control, in Healthy Male Volunteers	A Single-Centre, Double-blind, Double-dummy, Randomised, Placebo Controlled, Four Period Crossover Study to Assess the Effect of Single Oral Doses of AZD5672 (600mg and 150mg) on QT/QTc Interval, Compared to Placebo, using Moxifloxacin (Avelox®) as a Positive Control, in Healthy Male Volunteers	rheumatoid arthritis MedDRA version: 9.1;Level: HLT;Classification code 10039075;Term: Rheumatoid arthritis and associated conditions	Product Code: AZD5672 Trade Name: Avelox® Product Name: Avelox- Moxifloxacin	AstraZeneca AB	NULL	Not Recruiting			Female: no Male: yes	64		United Kingdom
2	NCT00887770 (ClinicalTrials.gov)	April 2009	23/4/2009	A Study to Investigate the Potential for AZD5672 to Affect the Electrical Conduction Pathways in the Heart	A Single-centre, Double-blind, Double-dummy, Randomised, Placebo-controlled, Four-period Crossover Study to Assess the Effect of Single Oral Doses of AZD5672 (600 mg and 150 mg) on QT/QTc Interval, Compared to Placebo, Using Moxifloxacin (Avelox®) as a Positive Control, in Healthy Male Volunteers	Rheumatoid Arthritis	Drug: AZD5672;Drug: Moxifloxacin;Drug: placebo	AstraZeneca	Quintiles Limited	Completed	18 Years	45 Years	Male	64	Phase 1	United Kingdom

49. Systemic lupus erythematosus

---

Clinical trials : 993 /  Drugs : 702 - (DrugBank : 184) / Drug target genes : 116 - Drug target pathways : 200

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03541564 (ClinicalTrials.gov)	May 30, 2018	17/5/2018	An Investigational Study of Experimental Medication BMS-986165 in Healthy Participants to Study Electrocardiogram Effects	A Randomized, Double-Blind, Positive-Controlled, Placebo-Controlled, 4-Period Crossover Study to Investigate the Electrocardiographic Effects of BMS-986165 in Healthy Subjects	Systemic Lupus Erythematosus;Healthy Participants	Drug: BMS-986165;Drug: Moxifloxacin;Other: Placebo	Bristol-Myers Squibb	NULL	Completed	18 Years	50 Years	All	84	Phase 1	United States

85. Idiopathic interstitial pneumonia

---

Clinical trials : 627 /  Drugs : 443 - (DrugBank : 120) / Drug target genes : 99 - Drug target pathways : 212

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	ChiCTR-TRC-12002372	2011-02-23	2012-07-15	Levofloxacin (Cravit) versus Moxifloxacin-concentration of epithelial lining fluid in patients with idiopathic pulmonary fibrosis (IPF)	Levofloxacin (Cravit) versus Moxifloxacin-concentration of epithelial lining fluid in patients with idiopathic pulmonary fibrosis	idiopathic pulmonary fibrosis	Cravit IPF Group:Cravit 500 mg per time;Cravit Normal Pulmonary Function Group:Cravit 500 mg per time;Moxifloxacin IPF Group:Moxifloxacin 400mg per time;Moxifloxacin Normal PulmonaryFunction Group:Moxifloxacin 400mg per time;	Respiratory Department, Peking Union Medical College Hospital	NULL	Completed	18	70	Both	Cravit IPF Group:12;Cravit Normal Pulmonary Function Group:12;Moxifloxacin IPF Group:12;Moxifloxacin Normal PulmonaryFunction Group:12;		China

86. Pulmonary arterial hypertension

---

Clinical trials : 1,205 /  Drugs : 684 - (DrugBank : 124) / Drug target genes : 100 - Drug target pathways : 193

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03489005 (ClinicalTrials.gov)	April 9, 2018	29/3/2018	Effect of BIA 5 1058 on Cardiac Repolarization	A Randomized, Double-blind, Placebo-controlled and Open-label, Active Controlled, 4 Period Crossover Trial to Evaluate the Effect of BIA 5 1058 on Cardiac Repolarization in Healthy Adult Males and Females Under Fed Conditions	Cardiovascular Disease;Pulmonary Arterial Hypertension;Heart Failure	Drug: BIA 5-1058;Drug: Placebo Oral Tablet;Drug: Moxifloxacin 400 mg	Bial - Portela C S.A.	Covance	Completed	18 Years	55 Years	All	49	Phase 1	United Kingdom

113. Muscular dystrophy

---

Clinical trials : 646 /  Drugs : 471 - (DrugBank : 105) / Drug target genes : 59 - Drug target pathways : 170

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04821063 (ClinicalTrials.gov)	April 13, 2021	26/3/2021	Placebo-Corrected Effects of Therapeutic Dose (100 mg) and Supratherapeutic Dose (300 mg) of ITF2357 (Givinostat) and Moxifloxacin on QT/QTC Interval	A Randomized, Partially Double-Blind, Four-Period, Four-Treatment, Crossover Study Investigating the Placebo-Corrected Effects of a Therapeutic Dose (100 mg) and a Supratherapeutic Dose (300 mg) of ITF2357 (Givinostat) and Moxifloxacin on QT/QTC Interval in Healthy Male and Female Subjects	Duchenne and Becker Muscular Dystrophy;Polycytemia Vera	Drug: ITF2357 10 mg/mL;Drug: Placebo;Drug: Moxifloxacin Hydrochloride	Italfarmaco	NULL	Completed	18 Years	55 Years	All	31	Phase 1	Canada

240. Phenylketonuria

---

Clinical trials : 143 /  Drugs : 90 - (DrugBank : 10) / Drug target gene : 1 - Drug target pathways : 5

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00789568 (ClinicalTrials.gov)	October 2008	10/11/2008	A Phase 1 Study to Evaluate Effects of Sapropterin Dihydrochloride on QTc Intervals in Healthy Adult Subjects	A Phase 1, Randomized, Placebo- and Active-controlled Crossover Study to Evaluate the Effects of Sapropterin Dihydrochloride Oral Administration on QTc Intervals in Healthy Adult Subjects	Phenylketonuria	Drug: sapropterin dihydrochloride;Drug: Moxifloxacin;Drug: Moxifloxacin placebo	BioMarin Pharmaceutical	NULL	Completed	18 Years	50 Years	All	56	Phase 1	United States

299. Cystic fibrosis

---

Clinical trials : 1,695 /  Drugs : 1,527 - (DrugBank : 268) / Drug target genes : 111 - Drug target pathways : 174

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01910415 (ClinicalTrials.gov)	June 2013	19/7/2013	Phase 1, QT/QTC Interval Study in Healthy Subjects	A Phase 1, Randomized, Placebo and Active Controlled, Double-Blind, Parallel, Electrocardiogram Study to Evaluate the Effect of Lumacaftor in Combination With Ivacaftor on the QT/QTc Interval in Healthy Subjects	Cystic Fibrosis	Drug: Lumacaftor;Drug: Lumacaftor Placebo;Drug: Ivacaftor;Drug: Ivacaftor Placebo;Drug: moxifloxacin hydrochloride	Vertex Pharmaceuticals Incorporated	NULL	Completed	18 Years	55 Years	Both	200	Phase 1	Netherlands

Back to top